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Identity 
Other names: MOM1, PLA2, PLA2B, PLA2L, 
PLA2S, PLAS1, sPLA2, sPLA2-IIA 




Background: The phospholipase A2 (PLA2s) 
superfamily, consisting of at least 34 members 
subdivided into at least 15 groups, is a group of 
intracellular and secreted enzymes that hydrolyzes th  
sn-2 ester bond in glycerophospholipids found in 
lipoproteins and cellular membranes to liberate fatty 
acids and lysophospholipids that can act as intracellular 
second messengers or are further  
metabolized into mediators of a variety of cellular 
processes such as inflammation, proliferation, 
apoptosis and atherogenesis. PLA2s are a diverse 
family of enzymes in terms of sequence, localization, 
function, and divalent cation requirements. PLA2s are 
classified into several groups based on their size, 
structure, and need for divalent cations. Groups I, II, 
and III all contain secreted forms of PLA2, which are 
extracellular enzymes that have a low molecular mass 
of ~14 kD and require calcium ions for catalysis. 
PLA2G2A belongs to the subfamily of group II 
sPLA2s, comprising PLA2 group IIA, PLA2 group IIC, 
PLA2 group IID, PLA2 group IIE, PLA2 group IIF, and 
PLA2 group V. All of these enzymes are encoded by a 
cluster of highly homologous genes located within a 
~250 kb genomic segment on human chromosome 
1p35, and on its homologous region on mouse distal 
chromosome 4. 
 
Figure 1. Structure of the PLA2G2A gene. 
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PLA2G2A was first identified following the isolation 
and sequencing of proteins from the synovial fluid of 
human rheumatoid arthritis. A cDNA library prepared 
from peritoneal exudate cells identified a full-length 
PLA2G2A 0.8 kb transcript and cDNA of 435 
nucleotides that encodes for a polypeptide of 144 
amino acids with a molecular mass of 16 kD (~14 kD 
in the mature peptide). The protein was found to 
demonstrate features of the type II class of PLA2s, 
including conserved catalytic residues and a Ca2+-
binding loop. 
Structure: The PLA2G2A gene is 4.98 kb in length, 
with 6 total exons and 4 protein coding exons. 
Transcription 










The PLA2G2A gene produces multiple transcripts 
arising from splice variants and alternative promoter 
usage. There are believed to be at least seven splice 
variants produced by usage of the predominant 
promoter. The gene contains 6 exons with 4 exons 
containing protein coding regions. Variants are 
produced that have different 5' UTRs. The longest and 
predominant transcript is NM_000300 with a processed 
length of 970 nt and a mRNA of 997 nt. This produces 
a mature mRNA (NP_000291.1) of 435 nt that encodes 
for a polypeptide of 144 amino acids. The different 
splice variants either encode for the same polypeptid  
or encode for no protein product. 
The PLA2G2A promoter contains TATA and CAAT 
boxes and elements with consensus sequences for 
binding of transcription factors such as AP-1, C/EBPs, 
CREB, NF-kB, STAT, LXR/RXR heterodimers, 
NFATs and PPARgamma. Although the promoter does 
not contain a typical CpG island there are CpG target 
sites at -82 and -111 and Sp1 binding may be inhibited 
by promoter hypermethylation. CpG sites also exist in 
the -1340 to -900 promoter region and in gastric cancer 
cell lines that did not express PLA2G2A these sites 
were hypermethylated, leading to PLA2G2A silencing. 
PLA2G2A has also been reported to be silenced by 
promoter hypermethylation in prostate cancer cells and
Jurkat leukemia cells. PLA2G2A is a direct target of 
Wnt/beta catenin signaling, with multiple TCF/LEF 
transcription factor binding sites in the -1340 to -920 
promoter region. 
Trans acting regulators of PLA2G2A transcription 
include: Sp1, NF-kB p65, Jak/STAT, Rho-kinase, and 
C/EBP-beta. Expression of musashi-1, a putative stem 
cell marker, suppresses PLA2G2A expression in cell 
culture at the mRNA level. Notch1 activates PLA2G2A 
within intestinal epithelial cells and forced expression 










The protein has a 20 amino acid signal sequence and a 
124 amino acid mature peptide with a molecular mass 
of ~14 kD. PLA2G2A has protein domains typical of 
Type II PLA2s that include a highly conserved catalytic 
region (DXCCXXHD) and a Ca2+-binding loop 
(XCGXGG). PLA2G2A also shares with other PLA2s 
the characteristic seven cysteine disulfide bridges that 
are important for regulation and protein stability. 
Expression 
PLA2G2A has been extensively studied in human 
tissues where its activity is associated with 
inflammation, host defense against bacteria, blood 
coagulation and atherosclerosis. PLA2G2A is 
expressed in prostate epithelial cells, coronary vascular 
smooth muscle cells, kidney uriniferous tubular 
epithelium, respiratory epithelial cells, pulmonary 
arterial smooth muscle cells, placenta, hepatocytes, 
stomach, small and large intestine, spleen, thymus, 
tonsil, parotid and lacrine glands, cartilage and bone 
marrow, seminal plasma, tears, platelets, neutrophils, 
eosinophils, mast cells, macrophages, and liver Kupfer 
cells. 
Many human cells can secrete PLA2G2A, including: 
mesangial cells, smooth muscle cells, endothelial cells, 
mast cells, neutrophils, macrophages, hepatic cells, 
platelets, Paneth cells, lacrimal cells, human tears, 
prostate cells, seminal plasma, chondrocytes, 
synoviocytes, and astrocytes. 
PLA2G2A is constitutively expressed in: spleen, 
thymus, tonsil, bone marrow, intestine (Paneth cells), 
liver (Kupfer cells), neutrophils, macrophages, mast 
cells, and Platelets. In these last 4 cell types PLA2G2A 
is stored in granules and secreted following cell 
activation. PLA2G2A is induced by inflammatory 
cytokines such as IL-6, TNF-alpha and IL-8 in smooth 
muscle cells and hepatocytes, which may be the main 
source of PLA2G2A in systemic inflammatory 
conditions. 
Function 
Overview: PLA2G2A is involved in arachidonic acid 
metabolism, production of lysophospholipid-derived 
mediators, antimicrobial activity, anticoagulation, 
exocytosis of endocrine cells, release of pro-
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inflammatory mediators, cell proliferation, ischemic 
injury and allergic disease, lipid modifications, and 
cancer. These functions are mediated by both enzyme 
catalytic and no-catalytic activities of PLA2G2A. 
Phospholipase Catalytic activity. One important 
feature that discriminates PLA2G2A from other group 
II PLA2 family members is its highly cationic nature. 
PLA2G2A is highly basic with a pI of 9.4 and a net 
charge of +19; the positive charge is distributed over 
the surface of the protein and this permits the protein to 
bind anionic phospholipids, to bind tightly to anioic 
heparanoids such as heparin and heparan sulphate 
proteoglycans (HPSGs), and to form supra molecular 
aggregates, and in general PLA2G2A prefers substrate  
in aggregates (e.g., micelles). Thus, a large proportion 
of PLA2G2A protein will stick to cell surface 
molecules, as has been observed for recombinant PLA2
transfected into HEK293 cells. When bound to 
glycerophosphatidylinositol-anchored HSPGs such as 
glypicans, PLA2G2A is transferred to punctate 
compartments containing caveolin. 
Substrate hydrolysis by PLA2G2A proceeds through 
activation and orientation of a water molecule by 
hydrogen bonding to the active site histidine. Adjacent 
to this histidine there is a conserved aspartate residu , 
which, together with the Ca2+-binding loop, acts as a 
ligand cage for Ca2+. The enzymatic reaction requires 
mM concentrations of Ca2+ and optimal substrate 
hydrolysis occurs at pH 7-9. PLA2G2A hydrolyzes the
ester bond at the sn-2 position of glycerophospholiids 
with no strict fatty acid selectivity. 
Enzymatically, the cationic nature of the PLA2G2A 
protein causes it to be much more effective in 
hydrolyzing fatty acids from negatively charged lipid 
membranes containing anionic phospholipids like 
phosphatidylserine (PS) than in releasing fatty acids 
from uncharged lipid membranes. The outer leaflets of 
unperturbed mammalian cells are characterized by 
neutral lipid composition enriched in 
phosphatidylcholines, sphingomyelin and cholesterol, 
thus unperturbed cells are poor substrates for 
extracellular PLA2G2A and thereby prevent 
indiscriminate hydrolysis of healthy cells. Consistent 
with this idea, healthy mammalian cells are highly 
resistant to exogenous PLA2G2A, requiring very high 
concentration of the protein to elicit arachidonic a id 
release. Perturbation of cell membranes by 
phospholipid scramblase that alters membrane 
symmetry increases PLA2G2A activity and arachidonic 
acid release. While PLA2G2A does not exhibit a strict 
selectivity for the types of fatty acids that are bing 
released, arachidonic acid is certainly one of its major 
hydrolytic products. Arachidonic acid can be processed 
by cyclooxygenases (COX's) and lipoxygenases 
(LOX's) to form eicosanoids including prostaglandins 
and leukotrienes. 
PLA2G2A activity is increased by association with the 
sulfated polysaccharides including heparanoids. In 
particular, arginine and lysine residues on the surface 
of PLA2G2A facilitates the binding of PLA2G2A to 
heparin and heparan sulfate proteoglycans. Under 
certain conditions sphingomyelin inhibits PLA2G2A 
enzyme activity. The high packing density of lipid 
bilayers rich in sphingomyelin hinders the penetration 
of PLA2G2A into the bilayer. Cholesterol counteracts 
the effect of sphingomyelin-based inhibition and 
enhances PLA2G2A hydrolysis. Ceramides also 
increase PLA2G2A activity and alter fatty acid 
specificity. Finally, the presence of oxidized 
phospholipids in vesicles facilitates PLA2G2A enzyme 
activity. 
Arachidonic acid metabolism. While PLA2G2A is 
clearly implicated in arachidonic acid release its 
relative importance in this activity in specific cells and 
tissues is still under investigation. cPLA2alpha/IVA-
PLA2 is considered to be the primary enzyme 
responsible for arachidonic acid release in many cells. 
In some cells IVA and PLA2G2A cooperate in 
arachidonic acid release and PGE2 production (e.g., as 
shown in rat gastric cells). In other cells PLA2G2A 
activity is dependent on the activity of cPLA2s. The 
reason that PLA2G2A is believed to be less of a key 
factor in arachidonic acid release is that PLA2G2A 
prefers to act on anionic phospholipids such as 
phosphatidyl glycerol, phosphatidyl ethanolamine and 
phosphatidyl serine in marked preference to charge 
neutral phospatidylcholine (PA>PE PS>PC). But the 
outer leaflet of mammalian cells (and in general the
extracellular environment) is normally zwitterionic 
(containing unperturbed phosphatidyl choline bilayers), 
making these cells refractory to hydrolysis; 
traumatized, necrotic and apoptotic cells are more 
susceptible to hydrolysis by PLA2G2A, one reason that
PLA2G2A has been proposed to play a role in 
apoptotic processes. PLA2G2A added exogenously is 
poorly capable of releasing arachidonic acid because 
PLA2G2A binds poorly to zwitterioninc 
phospatidylcholine on the outer leaflets of resting cells. 
PLA2G2A may release arachidonic acid from the 
membrane microdomains where cell activation-induced 
membrane rearrangements including altered 
phospholipid symmetry, phospholipid oxidation, 
altered membrane fluidity, and possible sphingomyelin 
turnover. 
PLA2G2A is involved in inflammation, an overview: 
PLA2G2A is induced during an inflammatory response 
by pro-inflammatory endotoxins and cytokines via both 
autocrine and paracrine processes and is involved in the 
acute phase of the immune responses. These stimuli 
can result from the action of microbial pathogens, 
chemical irritants, allergens and physical stress 
factors.PLA2G2A is an acute phase reactant and is 
found significantly increased in plasma in diseases that 
involve systemic inflammation such as sepsis, 
rheumatoid arthritis and cardiovascular diseases. For 
example, serum PLA2G2A concentrations can increase 
up to 1000 x fold in trauma and infection. Secreted 
PLA2G2A assists in the biosynthesis of lipid mediators 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(2)  201 
in inflammatory cells such as mast cells, macrophages, 
neutrophils and eosinophils. Anti-inflammatory 
glucacorticoids are a potent suppressor of the induce  
expression of PLA2G2A. However, in certain contexts 
the actions of PLA2G2A may be anti-inflammatory. It 
plays a role in the removal of cell debris and micro 
particles resulting from tissue trauma and downstream 
lipid mediators such as prostaglandins may prevent 
chronic inflammation in tissues such as the 
gastrointestinal tract. 
PLA2G2A, a pro-inflammatory factor. Since the 
identification of PLA2G2A from synovial fluid of 
patients with rheumatoid arthritis, high levels of 
PLA2G2A have been detected in many inflammatory, 
autoimmune, and allergic disease like acute 
pancreatitis, septic shock, adult respiratory distress 
syndrome, Crohn's disease, ulcerative colitis, bronchial 
asthma, and allergic rhinitis. Serum levels of 
PLA2G2A can serve as an index of disease activity in 
rheumatoid arthritis. Moreover, expression of 
PLA2G2A by inflammatory cells is induced by pro-
inflammatory stimuli like LPS, TNF-alpha, IL-1beta, 
IL-6, and IFN-gamma, and strongly repressed by anti-
inflammatory glucocorticoids, indicating that 
expression of PLA2G2A is strongly associated with, 
and regulated by inflammatory responses. The 
enzymatic activity of PLA2 enzymes results in the 
generation of bioactive molecules such as 
lysophospholipids and free fatty acids, of which the 
release of arachidonic acid is of particular interest 
because it is the first and rate-limiting step in the 
generation of eicosanoids. Free arachidonic acid is 
metabolized by COXs and LOXs into various 
prostaglandins and leukotrienes, respectively, bioact ve 
molecules that have a wide range of effects, including 
modulation of inflammatory responses. Although 
cPLA2 enzymes have been implicated in the release of 
arachidonic acid specifically for eicosanoid generation, 
there is functional coupling between sPLA2s and 
cPLA2. PLA2G2A and sPLA2-V have been 
demonstrated to enhance eicosanoid generation, e.g., by 
stimulating expression of inducible COX-2 in 
conjunction with other stimuli. COX-2 (also known as
prostaglandin H synthase-2) converts arachidonic acid
to PGH2, the immediate substrate for a variety of 
prostaglandin and thromboxane synthases. In the GI 
tract, COX-2 is best known for its promotion of 
inflammation, proliferation of cancer cells and 
resistance to apoptosis. Although the mechanisms 
through which sPLA2s stimulate COX-2 induction have 
not been completely resolved, sPLA2-mediated 
generation of lysophosphatidylcholine (lyso-PC) may 
play a role in this process. In addition, lyso-PC has 
been demonstrated to be a chemoattractant for 
monocytes, suggesting that sPLA2s mediate the influx 
of inflammatory cells during inflammation. In rodents, 
Pla2g2a and several other sPLA2s can also function as 
ligands for PLA2-binding proteins like the M-type 
PLA2 receptor PLA2R1. This receptor is expressed by 
various inflammatory cells like neutrophils and 
macrophages. Stimulation of the PLA2R1 by sPLA2s 
induces activation of signal transduction pathways 
involving p38 MAPK, ERK1/ERK2, 
phosphatidylinositol 3-kinase (PI3K) and Akt, and 
results in the induction of iNOS and the production of 
various cytokines that mediate inflammatory responses 
against bacterial infections. 
PLA2G2A is implicated in the development of 
inflammatory bowel disease (IBD) in both humans and
rodents. In humans, its mRNA and protein expression 
is upregulated in both ulcerative colitis and Crohn's 
Disease, with an increase in expression detected in the 
colonic mucosa, in the intestinal submucosa in mast 
cells and macrophages, and in the serum of IBD 
patients. In rodents, inhibitors of Pla2g2a protect rats 
from TNBS-induced colitis; mouse Pla2g2a is 
upregulated in the colonic mucosa following treatment 
with azoxymethane and dextran sulfate sodium (DSS) 
and PLA2G2A is a candidate for a quantitative trait 
locus (QTL) for experimental IBD. All together, these 
data indicate that PLA2G2A modulates inflammatory 
responses by attracting inflammatory cells and by 
stimulating the production of various mediators of 
inflammation, both through its enzymatic and its 
receptor-mediated actions. 
PLA2G2A, a potential anti-inflammatory factor. 
There is direct and indirect evidence that PLA2G2A 
may also act in an anti-inflammatory manner. Inbred 
strains of mice are naturally mutant or wildtype for the 
Pla2g2a allele. Several studies of gastric inflammation 
employing mice that expressed a wildtype allele of 
Pla2g2a, either as an endogenous copy or a transgene, 
clearly demonstrated that Pla2g2a+ mice were resistant 
to bacterially-induced gastric inflammation in 
comparison with C57BL/6 mice that expressed a 
mutant copy of Pla2g2a. In the DSS model of 
experimental IBD, C57BL/6 and Balb/c mice (Pla2g2a 
wildtype) were treated with DSS and it was observed 
that the C57BL/6 mice progressed to chronic 
inflammation while the Balb/c mice significantly 
upregulated production of PGE2, down-regulated 
expression of a great number of inflammatory 
cytokines and rapidly resolved the DSS-induced 
inflammation. This study indicated that PGE2 was 
protective against chronic inflammation, rather than a 
promoter of inflammation. Several other studies 
support this conclusion. DSS treatment of knockout 
mice that lack the 2 receptor caused a more severe 
colitis, greater mucosal damage, and enhanced 
proliferation of inflammatory CD4+ T cells when 
compared with EP4 wildtype mice. In rats, rectal 
injection of PGE2 following treatment with DSS caused 
the inhibition of tissue damage and the down-regulation 
of inflammatory cytokines. This finding was in 
agreement with the low levels of PGE2 observed upon 
enterocolitis relapse in the Lewis rat strain that is 
susceptible to relapse. PGE2 can also suppress Th1 
cytokine production (IL-12, IFN-gamma) in intestinal 
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macrophages, thereby helping to maintain resident 
macrophages in an anti-inflammatory mode. Indeed, 
COX-2 may have anti-inflammatory properties, and a 
number of studies suggest that inhibition of COX-2 and 
PGE2 can actually exacerbate IBD in mice. For 
example, in the IL-10 knockout model of colitis and 
inflammatory colon cancer, treatment of IL-10 
knockout mice with the COX-2 selective inhibitors 
celecoxib and rofecoxib greatly increased the incidence 
of colitis. Thus, the specific context is a major 
determinant of whether a molecule acts in an 
inflammatory or anti-inflammatory fashion and this 
may be true for PGE2. 
Normal bacterial flora play a key role in the 
development of colonic inflammation and 
inflammation-dependent and independent intestinal 
cancer, so it is quite likely that bactericidal factors such 
as PLA2G2A that are active in the intestinal crypt 
lumen may play an important role in management of 
gut flora, especially in the context of mucosal damage. 
Eicosanoids that are produced downstream of 
PLA2G2A are involved in both the initiation and 
resolution stages of inflammation and wound repair. 
This biphasic response involves multiple interacting 
factors that include PGE2, PGD2, PGJ2, plus the level of 
immune cell activation. This was demonstrated in a 
carrageenin-induced pleurisy model in rats where 
PLA2G2A was maximally produced in the resolution 
stage where it was associated with production of PGD2 
and PGI2. PLA2G2A has been associated with 
upregulation of lipoxin A4, a suppressor of leukocyte 
function that reduces inflammation and leukocyte 
infiltration, and platelet activating factor (PAF), a 
molecule that enhances macrophage phagocytosis of 
apoptotic cells. Recent studies of sepsis also call into 
question a pro-inflammatory role for PLA2G2A. In 
human clinical trials, PLA2G2A inhibition produced a 
negative survival trend in sepsis patients. Sepsis has 
traditionally been treated as an inflammatory disease, 
but very recent work indicates that elevated levels of 
inflammatory cytokines actually improve clinical 
outcome. Consistent with this observation studies in 
rodent models of peritonitis showed that blockage of 
TNF-alpha resulted in a reduction in animal survival. 
Similarly, combination therapy against TNF-alpha and 
the IL-1 receptor was fatal in a rodent model of sepsis, 
an effect that was also observed in a clinical trial of 
TNF-alpha antagonists. Thus, the increased levels of 
PLA2G2A observed in some inflammatory conditions 
may result in enhanced destruction of invasive flora, 
and this may help resolve both the infection and 
inflammation. Consistent with this idea is the 
significant clinical improvement of sepsis patients 
treated with statins, a molecule that induces both 
PLA2G2A and pro-inflammatory cytokines. These data 
suggest that PLA2G2A can promote the resolution of 
inflammatory responses, thereby contributing to the
prevention of chronic inflammation. 
PLA2G2A has potent bactericidal activity. The 
management of normal enteric and infectious bacterial 
flora by PLA2G2A in prevention of inflammatory 
disease in both mice and humans is well-documented. 
PLA2G2A is stored in secretory granules of platelets, 
neutrophils, mast cells, gastric cells, goblet cells and 
Paneth cells, and is also expressed by macrophages. 
These types of cells have a common function in the 
defense against microbacteria. PLA2G2A is 
particularly active against Gram+ bacterial cells where 
it demonstrates a preference for the inner cell 
membrane. The positively charged residues on the 
surface of the PLA2G2A protein allow it to penetrate 
through the negatively charged cell wall of Gram-
positive bacteria, where its enzymatic activity is 
responsible for membrane phospholipid degradation 
and ultimately bacterial killing. Overexpression of
human PLA2G2A in transgenic mice resulted in 
decreased mortality in experimental Staphylococcus 
aureus infection and improved clearance of bacteria 
from organs and body fluids, and provided protection 
against Bacillus anthracis infection. Hence, enzymatic 
activity of PLA2G2A forms a first line of defense 
against Gram-positive bacteria such as Bacillus, 
Listeria, Staphylococcus, Streptococcus, Enterococcus, 
and Clostridium. 
Gram-negative bacteria are coated with LPS. 
PLA2G2A exhibits only weak direct bactericidal 
activity against Gram-negative bacteria like 
Escherichia coli. Nevertheless, upon experimental E. 
coli infection, mice transgenic for wildtype Pla2g2a 
showed lower rates of mortality and less bacterial 
growth in tissues than their Pla2g2a-deficient C57BL/6 
littermates, indicating that PLA2G2A does play a role 
in defense against Gram-negative bacteria. In humans, 
chronic gastritis caused by the Gram-negative 
bacterium Helicobacter pylori is a strong risk factor for 
gastric cancer where H. pylori has been shown to 
activate beta catenin. Human PLA2G2A is bactericidal 
against H. pylori in vitro but H. pylori's effect is 
modeled in vivo in the stomach of mice via the use of 
the related species H. felis. Infection of C57BL/6 mice 
with H. felis causes severe gastritis that eventually 
results in neoplastic development. A key early event in 
this gastritis is the breakdown of the epithelial 
phospholipid barrier. In several H. felis studies, 
comparison of inbred mouse strains that expressed 
either a wildtype or mutant allele of Pla2g2a indicated 
that expression of wildtype Pla2g2a provided resistance 
to both inflammation and neoplastic development. The 
protective role of PLA2G2A was further demonstrated 
by another study in which the expression of a human 
transgene in C57BL/6 mice prevented infection with H. 
felis. In another study, Balb/c mice that expressed a 
wildtype Pla2g2a gene were shown to sharply 
upregulate Pla2g2a in the stomach upon challenge with 
H. felis, resulting in rapid resolution of the 
inflammation. These effects of Pla2g2a on Gram- 
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negative pathogens are probably due to receptor-
mediated activity rather than to direct bactericidal 
activity. Knockout mice that lack the M-type PLA2 
receptor Pla2r1 were demonstrated to be more resistant 
to LPS-induced endotoxic shock than their wild-type 
littermates. Hence, Pla2g2a and the PLA2R1 receptor 
are likely involved in the innate immune response 
against Gram-negative bacteria. Finally, in another 
study, C57BL/6-ApcMin/+ mice (Pla2g2a-negative) 
developed three-fold more colon tumors after infection 
with the naturally occurring Gram-negative bacterium 
Citrobacter rodentium. This study confirmed the 
oncogenic role of bacterial flora in colon 
carcinogenesis and emphasized the action of 
bactericidal agents such as Pla2g2a in management of 
gut flora to protect against tumorigenesis. 
Catalytic-independent activity by PLA2G2A. Some 
biological effects of PLA2G2A are independent of its 
catalytic functions: catalytically inactive mutants can 
enhance COX-2 expression in connective tissue mast 
cells and catalytically inactive mutants can induce 
secretion of beta-glucuronidase, IL-6 and IL-8 from 
human eosinophils. Signaling mediated by binding to 
ανβ3 and α4β3 integrins stimulates proliferation of 
monocytes. 
In rodents Pla2g2a binds to the 180 kDa M-type 
receptor, a cell surface protein that may be involved in 
important physiological functions that are mediated by 
the binding of PLA2's and other ligands. The M-type 
receptor is expressed in the colon, thus these receptors 
may have some importance in Pla2g2a's functions in 
intestinal tumorigenesis. Accordingly, there are reports 
that some functions of PLA2G2A do not rely on its 
hydrolytic activity, and that even arachidonic acid 
release can result solely from binding of PLA2G2A to 
its M-type cell surface receptor. Catalytically-inactive 
PLA2G2A mutants which were unable to cause the 
release of arachidonic acid from cytokine-primed mast 
cells still retained the ability to enhance COX-2 
expression. Furthermore, the ability of PLA2G2A to 
enhance EGFR activation in A431 cells is located in a 
separate amino terminal domain from the distal 
phospholipase domain, although it is notable that other 
sPLA2's can inhibit EGF induced receptor activation in 
A431 cells. Other reported PLA2G2A activities that are 
likely to be independent of its enzymatic activity are 
the induction of iNOS in murine macrophages and the 
release of cytokines from human monocytes, lung 
macrophages and eosinophils. 
PLA2G2A, arachidonic acid, and apoptosis. 
PLA2G2A has a preference for negatively charged 
lipid membranes containing anionic lipids like 
phosphatidylserine, due to its cationic nature. Theout r 
leaflets of lipid bilayers in unperturbed cells have a 
neutral lipid composition enriched in 
phosphatidylcholines, sphingomyelin, and cholesterol, 
and form a poor substrate for PLA2G2A. However, 
cells that are undergoing apoptosis lose their membrane 
asymmetry, resulting in exposure of anionic lipids to 
the outer leaflet, thereby increasing the affinity for 
PLA2G2A binding. Moreover, perturbed cell 
membranes are also found in cancer cells. Apoptosis of 
transformed cancer cells is an important defense 
mechanism against neoplastic development, and PLA2 
enzymes both promote and prevent apoptosis in 
different cell types under different pathological 
conditions. Addition of phospholipid scramblase, an 
enzyme that alters membrane symmetry, to HEK293 
cells, caused an increase in PLA2G2A activity, 
resulting in an increase in arachidonic acid release and 
a slowing in cellular proliferation. Arachidonic acid 
produced by PLA2G2A enzymatic activity promotes 
apoptosis in colon cancer cells and in many other types 
of normal and cancer cells. Exogenous arachidonic acid 
is cytotoxic to HCT-116 colon cancer cells and causes 
an increase in the expression of pro-apoptotic genes 
such as caspase-3 and c-Jun and a decrease in the 
expression of genes that promote cancer cell survival. 
In another study, exogenous arachidonic acid caused a 
dramatic increase in rates of apoptosis in HCT-116 and 
SW480 colon cancer cells, a phenotype that was 
associated with the activation of neutral 
sphingomyelinase resulting in the greatly enhanced 
production of ceramide. Sphingomyelinases and their 
sphingolipid products confer resistance to colon cacer, 
including the suppression of tumorigenesis in ApcMin/+ 
mice. Sphingomyelin in the outer leaflet of healthy 
cells is not a substrate for PLA2G2A and inhibits its 
activity. It is possible that sphingomyelinase may 
stimulate PLA2G2A by the removal of inhibitory 
sphingomyelins. It has been reported that TNF-alpha 
induces sphingomyelinase hydrolysis, resulting in 
PLA2G2A activation and arachidonic acid release. 
Cytosolic PLA2's resistance to AOM-induced colon 
tumors was associated with a sharp increase in 
ceramide production in cPLA2 wildtype mice versus 
knockout mice. A similar mechanism may contribute to 
PLA2G2A's mode of action as has been shown with 
other sPLA2's. Interestingly, factors that promote 
release of arachidonic acid from cells, such as Vitamin 
D3 and other nuclear receptor agonists promote 
apoptosis despite the concurrent increase in 
lipoxygenases. PLA2G2A also induces apoptosis in a 
wide range of non-colonic cells including neurons, 
astrocytes, fibroblasts, murine macrophages and NK 
and cytotoxic T cells. Finally, while PGE2 is generally 
considered as a pro-cell-survival factor, it does induce 
apoptosis in certain cell types such as brain glial cells 
where PGE2 activates BAX. 
PLA2G2A receptors. In mice and rabbits PLA2G2A 
binds to a 180 kDa M-type high affinity receptor but no 
receptor has been identified in humans. Binding to this 
receptor in mice induces Pla2g2a internalization. 
Human PLA2G2A has been shown to bind to integrins 
(such as ανβ3 and α4β3), and to heparan sulfate 
proteoglycans such as glypican 1 and decorin. 
Inducers and downstream effectors of sPLA2-IIA. 
Factors that stimulate PLA2G2A include bacterial 
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lipopolysaccarides (LPS), interleukin (IL)-1beta, IL-6, 
IL-8, tumor necrosis factor (TNF)-alpha, interferon 
(IFN)-gamma, phorbol esters, and cyclic AMP (cAMP) 
elevating agents. The PLA2G2A promoter has TATA 
and CAAT boxes and binding sites for AP-1, C/EBPs, 
CREB, NF-kappaB, STAT, PPAR-gamma, LXR/RXR 
heterodimers and NFATs. In some contexts PLA2G2A 
activation is dependent upon prior activation by cPLA 2 
and 12-LOX/15-LOX. Factors that inhibit PLA2G2A 
include TGF-beta, IL-10, epidermal growth factor 
(EGF), basic fibroblast growth factor (bFGF), platee  
derived growth factor (PDGF) and insulin growth 
factor (IGF). Some of the molecules and pathways that 
act downstream of PLA2G2A include ERK1/2, 
inducible nitric oxide synthase (iNOS) in RAW264.7 
macrophages, EGF, based on its ability to increase 
activation of EGF receptor (EGFR) in A431 cells, 
MUC16 in human conjunctive epithelium, and in 
human microvascular cells PLA2G2A induces NF-
kappaB, intercellular adhesion molecule (ICAM)-1, IL-
8, epithelial derived neutrophil activating peptide 
(ENA)-78/CXCL5 and growth regulated protein Gro-
alpha/CXCL1. 
Homology 
PLA2G2A is conserved in mice, rats, chimpanzees, 
cows and chickens. 
Mutations 
Somatic 





PLA2G2A expression is positively associated with 
resistance to human gastric cancer progression. 
PLA2G2A is a direct target of Wnt/beta catenin 
signaling in human gastric cancer; its expression is 
silenced by hypermethylation of promoter elements that
contain beta catenin target sites; expression of 
PLA2G2A suppressed gastric cancer migration and 
invasion in cell culture and this phenotype was 
mediated by the inhibition of S100A4 and NEDD9; 
hemizygous gene deletions were found in at least two 
human gastric cancer cell lines. 
Colorectal cancer 
Note 
The role of PLA2G2a in human colorectal cancer is 
unclear. In one study, expression of PLA2G2A was 
found to decline with cancer progression. Other studies 
have found that PLA2G2A is upregulated in human 
colon adenomas; that expression of PLA2G2A is 
associated with shorter disease free survival; that 
PLA2G2A is upregulated in MSI+ colorectal cancers 
but down-regulated in APC-dependent colorectal 
cancers; and another study found that PLA2G2A is 
highly expressed in normal colon mucosa but its 
expression did not vary in adenocarcinomas. With the 
exception of a single European family, there are no 
reports of mutations in PLA2G2A that are implicated in 
differential risk for familial colorectal cancer. 
However, PLA2G2A lies in a region of chromosome 
one that is frequently subject to LOH in a variety of 
human epithelial cancers, including colorectal cancers. 
Mouse strains that are naturally mutant for a truncation 
mutation that eliminates the Pla2g2a catalytic region in 
the protein (e.g., C57BL/6) are susceptible to intestinal 
tumorigenesis, compared with strains that express a 
wildtype Pla2g2a allele. Introduction of a wildtype 
Pla2g2a transgene into the susceptible C57BL/6 strain 
caused a significant reduction in tumor multiplicity, 
tumor size and progression in several mouse models of 
intestinal cancer, including ApcMin/+ mice, Muc2 
knockout mice and mice treated with azoxymethane. 
Pancreatic cancer 
Note 




There is one report showing that expression of 
PLA2G2A is downregulated in metastatic human 
prostate cancer.  
However, many more groups have reported that 
expression of PLA2G2A is upregulated at all stages of 
prostate cancer with one report indicating that its 
upregulation may be androgen inducible. 
Ovarian cancer 
Note 




Aberrant expression of PLA2G2A has been reported in 
breast cancer. 
Familial adenomatous polyposis (FAP) 
Note 
PLA2G2A is reported to be a modifier for fundic gland 
polyposis in FAP patients. 
Gastric gland metaplasia 
Note 
Increased levels of PLA2G2A are associated with 
gastric gland metaplasia. 
Inflammation 
Note 
Upregulation of PLA2G2A is associated with a variety 
of inflammatory conditions. For example, large 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(2)  205 
amounts of PLA2G2A is detected in exudating fluids 
and plasma of patients with various systemic and local 
inflammatory diseases such as Crohn's disease, 
ulcerative colitis, sepsis, psoriasis, arthritis, respiratory 
distress syndrome, and asthma. While the 
predominance of evidence links PLA2G2A to the 
promotion of inflammation, there is also some evidence 
that PLA2G2A, in some specific contexts, may exert 
anti-inflammatory actions, such as by its management 
of flora, its involvement in removal of cell debris and 
micro particles resulting from tissue trauma, and by 
production of anti-inflammatory lipid mediators, 
including a variety of eicosanoids. 
Atherosclerosis 
Note 
PLA2G2A expression is increased in atherosclerotic 
lesions and its expression is associated with a decrease 
in levels of high density lipoprotein and in one report 
expression of PLA2G2A in macrophages is proposed to 
be the source of the upregulation. PLA2G2A can also 
modify LDL leading to more pronounced lipid 
accumulation in the vessel wall. 
Acute myocardial infarction 
Note 




Increased levels of PLA2G2A are reported in infracted 
kidneys, in the uriniferoustubular epithelium. 
Viral hepatitis 
Note 
Levels of PLA2G2A are increased in hepatocytes with 
fatty degeneration associated with viral hepatitis C. 
Ischemia 
Note 
PLA2G2A-induced changes in phospholipid integrity 
and toxic actions of free fatty acids and 
lysophospolipids may be critical for altered plasma 
membrane and mitochondrial permeability properties 
associated with ischemia and perfusion. 
Coronary heart disease 
Note 
An increase in circulating PLA2G2A is associated with 
unstable angina and is considered a risk factor for 
cardiovascular disease; PLA2G2A is increased in 




Expression of PLA2G2A is increased in patients with 




Dysregulation of PLA2G2A is associated with 
Alzheimer disease, stroke, oxidative pathways in 
astrocytes and cortical neurons, apoptosis in neurons. 
Other disorders 
Note 
Aberrant expression of PLA2G2A has been reported in 
glaucoma, pancreatitis, schizophrenia, affective 
disorder, diabetes. 
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